Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines
To counter the pandemic caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), some have proposed accelerating SARS-CoV-2 vaccine development
through controlled human infection (or 'challenge') trials. These trials would involve the
deliberate exposure of relatively few young, healthy volunteers to SARS-CoV-2. We defend
this proposal against the charge that there is still too much uncertainty surrounding the risks
of COVID-19 to responsibly run such a trial.
(SARS-CoV-2), some have proposed accelerating SARS-CoV-2 vaccine development
through controlled human infection (or 'challenge') trials. These trials would involve the
deliberate exposure of relatively few young, healthy volunteers to SARS-CoV-2. We defend
this proposal against the charge that there is still too much uncertainty surrounding the risks
of COVID-19 to responsibly run such a trial.
To counter the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), some have proposed accelerating SARS-CoV-2 vaccine development through controlled human infection (or ‘challenge’) trials. These trials would involve the deliberate exposure of relatively few young, healthy volunteers to SARS-CoV-2. We defend this proposal against the charge that there is still too much uncertainty surrounding the risks of COVID-19 to responsibly run such a trial.
jme.bmj.com